Study to Assess the Efficacy and Safety of Sitagliptin in Recently Diagnosed, Naive Type 2 Diabetics With Inadequate Glycemic Control on Diet and Exercise (0431-158)

• Status: Completed
• Trial end date: 2008-07-11
• Target enrollment: 0
• Participant gender: All

Summary

After 24 weeks of treatment evaluate the efficacy and security.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Sitagliptin Phosphate

Criteria

Inclusion Criteria:

• Patients Being Treated With Metformin

• Patients With Hba1c Between 6.5 % And 12.0%.

• Type 2 DM